HomeComparePRVB vs EQR

PRVB vs EQR: Dividend Comparison 2026

PRVB yields 8.01% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $13.8K in total portfolio value· pulled ahead in Year 4
10 years
PRVB
PRVB
● Live price
8.01%
Share price
$24.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.0K
Annual income
$1,328.87
Full PRVB calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PRVB vs EQR

📍 EQR pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRVBEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRVB + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRVB pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRVB
Annual income on $10K today (after 15% tax)
$680.54/yr
After 10yr DRIP, annual income (after tax)
$1,129.54/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $3,524.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRVB + EQR for your $10,000?

PRVB: 50%EQR: 50%
100% EQR50/50100% PRVB
Portfolio after 10yr
$40.9K
Annual income
$3,402.23/yr
Blended yield
8.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PRVB
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
8.7
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRVB buys
0
EQR buys
0
No recent congressional trades found for PRVB or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRVBEQR
Forward yield8.01%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$34.0K$47.8K
Annual income after 10y$1,328.87$5,475.61
Total dividends collected$10.7K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: PRVB vs EQR ($10,000, DRIP)

YearPRVB PortfolioPRVB Income/yrEQR PortfolioEQR Income/yrGap
1$11,501$800.64$11,380$679.82+$121.00PRVB
2$13,166$860.55$13,014$837.25+$152.00PRVB
3$15,009$920.73$14,961$1,036.20+$48.00PRVB
4← crossover$17,040$980.90$17,297$1,289.22$257.00EQR
5$19,274$1,040.82$20,121$1,613.15$847.00EQR
6$21,723$1,100.23$23,561$2,030.84$1.8KEQR
7$24,403$1,158.93$27,783$2,573.54$3.4KEQR
8$27,328$1,216.71$33,013$3,284.39$5.7KEQR
9$30,514$1,273.41$39,547$4,223.51$9.0KEQR
10$33,979$1,328.87$47,791$5,475.61$13.8KEQR

PRVB vs EQR: Complete Analysis 2026

PRVBStock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Full PRVB Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PRVB vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRVB vs SCHDPRVB vs JEPIPRVB vs OPRVB vs KOPRVB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.